|
Pacira Biosciences inc (NASDAQ: PCRX) |
|
Pacira Biosciences inc
PCRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Pacira Biosciences Inc 's sales fell
by -0.53 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1676
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.73 %
Pacira Biosciences Inc faced net loss in contrast to the net income a year ago in III. Quarter 2024
• More on PCRX's Growth
|
|
Pacira Biosciences Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8.75 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.35.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
• More on PCRX's Valuation
|
|
|
|
|
Pacira Biosciences Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 8.75 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.35.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.16.
Pacira Biosciences Inc Price to Book Ratio is at 1.22 lower than Industry Avg. of 79.2. and higher than S&P 500 Avg. of 0.01
• More on PCRX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com